New combo therapy shows promise for tough lymphoma
NCT ID NCT04257578
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 34 times
Summary
This early-phase study tests whether adding the drug acalabrutinib to a type of immune cell therapy (CAR T-cells) can safely treat B-cell lymphoma, a cancer of the immune system. About 23 adults with certain aggressive or slow-growing lymphomas will receive the combination. The goal is to see if the drug helps the immune cells work better and reduces side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.